Muscle Pharm Corp. announced unaudited financial results for the first quarter ended March 31, 2014. Net sales increased 123% to $50.2 million from $22.6 million last year, primarily as a result of increased market penetration both domestically and internationally. A key area of growth was international sales, which increased 176% to $17.2 million, or 34.3% of net sales, from $6.3 million last year, or 27.7% of net sales. Net income was approximately $2.7 million or $0.23 per diluted share compared with a net loss of approximately $7.4 million or $1.78 per diluted share for the same period last year. Results were fueled by strong international sales, which it believes will continue to present significant opportunities for the company. Income from operations was $2.42 million compared to loss from operations of $0.72 million reported a year ago.

The company has revised its full-year guidance for 2014. The company expects 2014 full-year net sales of approximately $165 million to $175 million and diluted earnings per share in the range of $0.41 to $0.51.